Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

45.92
-0.2800-0.61%
Post-market: 46.840.9196+2.00%19:50 EDT
Volume:1.30M
Turnover:59.45M
Market Cap:3.25B
PE:-19.25
High:46.54
Open:46.10
Low:44.77
Close:46.20
52wk High:94.90
52wk Low:13.22
Shares:70.84M
Float Shares:51.39M
Volume Ratio:1.46
T/O Rate:2.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3852
EPS(LYR):-2.3276
ROE:-11.86%
ROA:-9.39%
PB:2.15
PE(LYR):-19.73

Loading ...

Structure Therapeutics Obesity Trial Success Puts Valuation Gap In Focus

Simply Wall St.
·
Yesterday

LifeSci Capital Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Mar 21

This biotech is working on a GLP-1 pill that could be better than the Wegovy version

Dow Jones
·
Mar 18

Eli Lilly Shares Decline Over 4% as Structure Therapeutics Reports Positive Data for Experimental Weight-Loss Drug

Stock News
·
Mar 17

Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia

Reuters
·
Mar 17

Structure Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $100 From $114

THOMSON REUTERS
·
Mar 16

BUZZ-U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp

Reuters
·
Mar 16

Structure’s GLP-1 pill could put company on M&A radar, Barron’s says

TIPRANKS
·
Mar 16

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate? -- Barrons.com

Dow Jones
·
Mar 16

Structure Therapeutics Shares up 6% After Disclosing Mid-Stage Trial Results of Experimental Obesity Pill

THOMSON REUTERS
·
Mar 16

Structure Stock Rises on Positive Data From Oral GLP-1 Study

Dow Jones
·
Mar 16

This biotech is working on an GLP-1 drug that could be better than the Wegovy pill

Dow Jones
·
Mar 16

BRIEF-Structure Therapeutics Reports Positive Topline Data From Phase 2 Access Ii Trial With Once-Daily Oral Small Molecule Glp-1 Receptor Agonist, Aleniglipron

Reuters
·
Mar 16

Structure Therapeutics Shares Reverse Course; Last up 13.5% Premarket After Disclosing Mid-Stage Trial Results of Experimental Obesity Pill

THOMSON REUTERS
·
Mar 16

Structure Therapeutics Shares Down 1.6% Premarket After Disclosing Mid-Stage Trial Results of Experimental Obesity Pill

THOMSON REUTERS
·
Mar 16

Structure's obesity pill shows up to 16.3% weight loss in study

Reuters
·
Mar 16

Structure Therapeutics reports 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II trial of oral GLP-1 agonist aleniglipron

Reuters
·
Mar 16

Structure Therapeutics Inc - Interim Data Shows 2.0%-3.4% Ae-Related Discontinuations With 2.5 Mg Starting Dose

THOMSON REUTERS
·
Mar 16

Structure Therapeutics Inc - Access Ole Study Shows Continued Weight Loss up to 16.2% With 120 Mg at 56 Weeks

THOMSON REUTERS
·
Mar 16